Next-Generation Antibody Discovery and Development Technology

下一代抗体发现和开发技术

• 批准号: 9174883
• 负责人: David Scott Johnson
• 金额: $ 87.98万
• 依托单位: GIGAGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9174883
• 关键词: Accounting; Address; Affinity; Antibodies; Antigens; B cell repertoire; B-Lymphocytes; Biological Products; Biotechnology; Blood; CLIA certified; Cancer Patient; Capital; Cells; Cessation of life; DNA; DNA Library; DNA Sequence; Development; Diagnosis; Diagnostic; Diagnostic tests; Directed Molecular Evolution; Disease; Doctor of Philosophy; Engineering; Flavoring; Flow Cytometry; Genomics; Human; Hybridomas; Immune; Immunization; In Vitro; Innovation Corps; Interview; Investments; Lead; Libraries; Link; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Methods; Microfluidics; Molecular; Monoclonal Antibodies; Mus; Phage Display; Pharmaceutical Preparations; Pharmacotherapy; Phase; Proteins; Scientist; Screening for cancer; Sensitivity and Specificity; Sequoia; Services; Small Business Innovation Research Grant; Specialist; Technology; Therapeutic; Therapeutic antibodies; Time; Trastuzumab; Treatment Cost; United States National Institutes of Health; antibody libraries; base; bevacizumab; cancer therapy; commercialization; inhibitor/antagonist; interest; killings; new technology; next generation; novel; novel therapeutics; oncology; oncology program; product development; programs; research and development; rituximab; screening; technology development; tumor immunology

PROJECT SUMMARY Project Title: Next-Generation Antibody Discovery and Development Technology Organization: GigaGen Inc. PI: David S. Johnson, Ph.D. Despite an enormous investment in novel therapies, cancer still accounts for 25% of US deaths, killing >1500 people every day. For example, only 25% of pancreatic cancer patients and 17% of lung cancer patients survive one year after diagnosis. Additionally, oncology treatments cost $127 billion per year in the US, and are expected to grow at 27% per year through 2020. Monoclonal antibodies (mAbs) are now the biological agents of choice for cancer therapy. Three of the top six grossing therapeutics worldwide (bevacizumab, rituximab, and trastuzumab) are oncology mAbs. Today, most mAb discovery programs use either some flavor of single chain variable fragment (scFv) display or mouse immunization followed by hybridoma isolation. Display technologies like phage display have tremendous ease of use, which enables R&D programs to screen through billions of antibodies in parallel. Unlike conventional phage display technologies, mouse immunizations produce fully natural antibodies, which are often easier to develop than antibodies discovered through display. Though display and mouse immunizations have produced breakthrough therapeutic antibodies, R&D programs are always looking for faster, deeper, and more efficient antibody technologies. The Specific Aim of this IMAT Phase II SBIR project is to develop GigaLink™, a next-generation high-throughput molecular technology for discovery and development of oncology drugs from mammalian B cell repertoires. GigaLink™ is the only technology that uses primary B cells to make millions- to billions-diverse DNA libraries of antibodies, and then expresses the DNA libraries as protein for affinity screening and antigen discovery. As a DNA-based technology, GigaLink™ uniquely enables massively parallel antibody screening, engineering, and development. A successful IMAT Phase II SBIR project will show that the GigaLink™ antibody R&D platform can help our customers understand basic tumor immunology and discover and develop therapeutic antibody candidates. We will use the profits from GigaLink™ service revenues plus venture capital to build our own internal programs for oncology therapeutic antibody discovery.

项目摘要 项目名称：新一代抗体发现和开发技术 Registrant Organization：liu hanlin PI：大卫S.约翰逊博士 尽管在新疗法上投入了大量资金，但癌症仍占美国死亡人数的25%，死亡人数超过1500人。 人们每天。例如，只有25%的胰腺癌患者和17%的肺癌患者 确诊后一年内存活。此外，在美国，肿瘤治疗每年花费1270亿美元， 预计到2020年，每年将增长27%。 单克隆抗体（mAb）现在是用于癌症治疗的选择的生物制剂。前六名中的三个 全世界最大的治疗剂（贝伐单抗、利妥昔单抗和曲妥单抗）是肿瘤学mAb。今天大部分 mAb发现程序使用单链可变片段（scFv）展示或小鼠抗体（mAb）展示。 免疫接种，然后杂交瘤分离。像噬菌体展示这样的展示技术 这使得研发项目能够并行筛选数十亿种抗体。不同于常规 噬菌体展示技术，小鼠免疫产生完全天然的抗体，这往往是更容易， 比通过展示发现的抗体发展。 尽管展示和小鼠免疫已经产生了突破性的治疗性抗体， 一直在寻找更快、更深、更有效的抗体技术。IMAT的具体目标 第二阶段SBIR项目是开发GigaLink™，这是一种新一代高通量分子技术，用于 从哺乳动物B细胞库发现和开发肿瘤药物。GigaLink™是唯一 利用原代B细胞制造数百万到数十亿种不同的抗体DNA文库， 将DNA文库表达为用于亲和筛选和抗原发现的蛋白质。作为一种基于DNA的 技术，GigaLink™独特地实现了大规模并行抗体筛选、工程化和 发展 一个成功的IMAT第二阶段SBIR项目将表明，GigaLink™抗体研发平台可以帮助我们的 客户了解基本的肿瘤免疫学，并发现和开发治疗性候选抗体。 我们将利用GigaLink™服务收入和风险资本的利润，建立我们自己的内部 肿瘤治疗抗体发现的项目。